<DOC>
	<DOC>NCT00085956</DOC>
	<brief_summary>The purposes of this study are to determine: - The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. - The effects of arzoxifene on the uterus (womb) in postmenopausal women. - The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density. - The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk. - The safety of arzoxifene and any side effects that might be associated with its use.</brief_summary>
	<brief_title>Effects of Arzoxifene on Bone Mass and the Uterus</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<criteria>Female 45 to 60 years of age, inclusive At least 2 years since last menstrual cycle Intact uterus (womb). Existing fracture of the spine. Bone disorders, other than low bone mass History of cancer in the last 5 years. Also, any history, at any time, of breast cancer or cancer of the lining of the uterus. Abnormal or unexplained vaginal bleeding.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>